文献速递慢性肾脏病血液净化与透析

未接受透析治疗的晚期慢性肾脏病老年患者的生存、症状与住院情况

Survival, symptoms and hospitalization of older patients with advanced chronic kidney disease managed without dialysis.
PubMed 文献 · Nephrol Dial Transplant · 2023-01-01

这项前瞻性观察研究纳入510例≥65岁CKD 4-5期患者(保守肾管理280例、透析230例),发现保守肾管理患者从中位生存14个月(自治疗方式决策起)低于透析的53个月,但非计划住院率约为透析组的一半,且59%的保守肾管理患者第三次肾脏支持治疗门诊随访时症状改善。

要点

  • 保守肾管理患者自治疗方式决策起中位生存14个月,透析患者为53个月。
  • 透析队列非计划住院率是保守肾管理队列的2倍。
  • 59%的保守肾管理患者第三次随访时症状改善。

核心结论

  • 保守肾管理患者自治疗方式选择起中位生存14个月,住院率低于透析患者。
  • 晚期CKD症状负担高,但通过整合肾脏支持治疗项目管理的多数老年保守肾管理患者症状可随时间改善。
  • 这些数据可能有助于共同决策。

研究设计与样本

  • 前瞻性观察研究,在一家由多学科肾脏支持治疗项目支持的单元开展。
  • 纳入510例≥65岁CKD 4期和5期患者,其中保守肾管理280例、透析230例。
  • 生存分析采用logistic回归和Cox比例风险模型,症状随时间变化采用线性混合模型评估。

主要发现

  • 保守肾管理患者更年长(平均84岁 vs 74岁;P < .001),且有三种及以上合并症的可能性几乎高2倍(P < .001)。
  • 自治疗方式决策或透析开始日期起,保守肾管理中位生存14个月(IQR 6-32) vs 透析53个月(IQR 28-103)(P < .001)。
  • 自eGFR ≤15 mL/min/1.73 m2起,保守肾管理中位生存15个月(IQR 7-34) vs 透析64个月(IQR 30-103)(P < .001);自eGFR ≤10 mL/min/1.73 m2起,保守肾管理8个月(IQR 3-18) vs 透析49个月(IQR 19-101)。
  • 59%的保守肾管理患者报告第三次肾脏支持治疗门诊随访时症状改善(P < .001)。
  • 透析队列非计划住院率是保守肾管理队列的2倍。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Shared decision-making (SDM) is important when considering whether an older patient with advanced chronic kidney disease (CKD) should be managed with dialysis or conservative kidney management (CKM). Physicians may find these conversations difficult because of the relative paucity of data on patients managed without dialysis. METHODS: This prospective observational study was conducted in a unit supported by a multidisciplinary Kidney Supportive Care (KSC) programme, in a cohort of 510 patients (280 CKM and 230 dialysis) ≥65 years of age with CKD stages 4 and 5. Survival was evaluated using logistic regression and Cox proportional hazards models. Linear mixed models were utilized to assess symptoms over time. RESULTS: CKM patients were older (mean 84 versus 74 years; P < .001) and almost 2-fold more likely to have three or more comorbidities (P < .001). The median survival of CKM patients was lower compared with dialysis from all time points: 14 months [interquartile range (IQR) 6-32] versus 53 (IQR 28-103) from decision of treatment modality or dialysis start date (P < .001); 15 months (IQR 7-34) versus 64 (IQR 30-103) from the time the estimated glomerular filtration rate (eGFR) was ≤15 mL/min/1.73 m2 (P < .001); and 8 months (IQR 3-18) versus 49 (19-101) from eGFR ≤10 mL/min/1.73 m2. A total of 59% of CKM patients reported an improvement in symptoms by their third KSC clinic visit (P < .001). The rate of unplanned hospitalization was 2-fold higher in the dialysis cohort. CONCLUSIONS: CKM patients survive a median of 14 months from the time of modality choice and have a lower rate of hospitalization than dialysis patients. Although the symptom burden in advanced CKD is high, most elderly CKM patients managed through an integrated KSC programme and can achieve improvement in their symptoms over time. These data might help with SDM.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Chou A, Li C, Farshid S, et al. Survival, symptoms and hospitalization of older patients with advanced chronic kidney disease managed without dialysis. Nephrol Dial Transplant. 2023. PMID: 35438786. doi:10.1093/ndt/gfac154

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。